The Budget Impact of Biosimilar Infliximab (Remsima(A (R))) for the Treatment of Autoimmune Diseases in Five European Countries

摘要

Inflammatory autoimmune diseases (rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, and psoriatic arthritis) have a considerable impact on patients' quality of life and healthcare budgets. Biosimilar infliximab (Remsima(A (R))) has been authorized by the European Medicines Agency for the management of inflammatory autoimmune diseases based on a data package demonstrating efficacy, safety, and quality comparable to the reference infliximab product (Remicade(A (R))). This analysis aims to estimate the 1-year budget impact of the introduction of Remsima in five European countries.